Sensirion to start production of SHT21 sensor

Published: 29-Mar-2010
Regulatory

Swiss manufacturer says it is the smallest digital humidity sensor in the world

Sensirion, a Swiss manufacturer of CMOS-based sensor components and systems, is to begin serial production of the SHT21 next month (April).

The SHT21 consists of a newly designed sensor chip encapsulated in a DFN 3-0 package. With this encapsulation the chip is completely over-moulded, except for the humidity sensing area. This reduces the component’s size to 3x3mm with a height of 1.1mm. The company says it also provides protection against condensation and harsh environments, therefore giving outstanding long-term stability.

Typical sensor accuracy is ±2% RH over 20–80% RH and ±0.3 °C over 25–42°C.

A scan path routine enables detailed sensor quality checking, while individual detailed tracking information on the chip can be read out by a simple command. Additionally, the SHT21 is reflow solderable without any degradation of sensor performance. The sensor is provided on tape and reel to facilitate trouble-free handling.

See more

You may also like

Manufacturing

CARBOGEN AMCIS introduces SPRINT for early-phase development

Read more
A new, phase-appropriate approach designed to accelerate early-phase progression while maintaining scientific rigour

Trending Articles

  1. FDA approves AstraZeneca's FASENRA for hypereosinophilic syndrome AstraZeneca's FASENRA has received FDA approval for hypereosinophilic syndrome in adults and adolescents aged 12 and above, based on Phase III NATRON trial data showing a 65% reduction in the risk of first HES flare compared to placebo
  2. FDA issues first cGMP warning letter citing AI misuse in pharmaceutical manufacturing A Michigan-based lab has become the subject of the FDA's first dedicated enforcement action on artificial intelligence misuse in drug manufacturing — a landmark event with far-reaching implications for cGMP compliance across the pharmaceutical supply chain
  3. How the QA and QP Talent Market Is Changing in Pharma: Insights from Compliance Unlocked Podcast Recruiting and retaining experienced quality and regulatory professionals has become significantly more complex for pharmaceutical and biotech companies
  4. CARBOGEN AMCIS Shanghai site achieves successful outcome in unannounced NMPA GMP inspection China’s NMPA confirms robust GMP compliance at CARBOGEN AMCIS Shanghai, with no observations identified following an on-site unannounced inspection
  5. NSF Founded in 1944, NSF’s mission is to protect and improve global human health. NSF, Pharmaceutical Services provides a comprehensive range of independent, third-party pharmaceutical and biotech support services for the pharmaceutical industry. These services are delivered by some of the most knowledgeable experts in their fields. Whether you’re looking for pharmaceutical consulting, training, auditing or regulatory guidance, you can trust the experts at NSF.

Upcoming event

Cleanroom Technology Conference UK

20-21 May 2026 | Conference and Exhibition | Birmingham, UK See all

You may also like

Manufacturing

CARBOGEN AMCIS introduces SPRINT for early-phase development

A new, phase-appropriate approach designed to accelerate early-phase progression while maintaining scientific rigour
Manufacturing

How the QA and QP talent market is changing in pharma

Recruiting and retaining experienced quality and regulatory professionals has become significantly more complex for pharmaceutical and biotech companies
Regulatory

Andelyn Biosciences strengthens CDMO credentials with full ICMC certification

The certification received by Andelyn underscores their long-standing commitment to quality, operational readiness, and client service as the company supports innovators in advancing gene therapies from development through clinical and commercial manufacturing
Regulatory

MHRA approves beremagene geperpavec gene therapy gel for DEB from birth

The MHRA has approved beremagene geperpavec (Vyjuvek), a topical gene therapy gel for wounds in patients with dystrophic epidermolysis bullosa (DEB), for use from birth onwards
Regulatory

FDA approves AstraZeneca's FASENRA for hypereosinophilic syndrome

AstraZeneca's FASENRA has received FDA approval for hypereosinophilic syndrome in adults and adolescents aged 12 and above, based on Phase III NATRON trial data showing a 65% reduction in the risk of first HES flare compared to placebo
Manufacturing

Anxine responds to rising demand for integrated turnkey packaging solutions

Anxine has observed that more customers are moving away from purchasing individual machines and are instead choosing complete one-stop turnkey solutions that are easier to plan, manage, and put into operation
Regulatory

How the QA and QP Talent Market Is Changing in Pharma: Insights from Compliance Unlocked Podcast

Recruiting and retaining experienced quality and regulatory professionals has become significantly more complex for pharmaceutical and biotech companies
Subscribe now